Shao Y, et al. - In this single-centre prospective observational controlled cohort study, the researchers examined the impact of Ramadan fasting and continuing sodium-glucose co-transporter-2 (SGLT2) inhibitor use on ketonemia, blood pressure and renal function in Muslim patients with type 2 diabetes. In this investigation, Muslim patients aged 21 to 75 years with type 2 diabetes and estimated glomerular filtration rate (eGFR) ≥ 45 ml/min/1.73 m² were qualified in the event that they had no contraindication to observe Ramadan fasting. Regardless whether patients were on SGLT2 inhibitor treatment, Ramadan fasting was associated with significant changes in weight, BP and eGFR. It was observed in the findings that continued use of SGLT2 Inhibitors during Ramadan did not increase ketonemia, nor increase the risk of eGFR deterioration and hypoglycaemia.